Infliximab

Using infliximab to treat Crohn’s disease Introduction Crohn’s disease is a type of IBD that causes inflammation in any part gastrointestinal tract from the mouth to the anus. In response to this inflammation, the body’s immune system attacks the GI tract (Dessein, 2008). The progression of this chronic inflammatory disease is brought about by the action of several cellular processes and pro-inflammatory mediators (Poggioli, 2007). Because there is no single factor that can be targeted to stop the development of Crohn’s disease, there is no cure for it. However, certain drugs can be used to target specific mediators in order to treat the disease. Infliximab is an example of a drug that is used to treat CD by targeting a proinflammatory cytokine called tumour necrosis factor-α (Colombel, 2010). Mechanism of action of Infliximab Tumour necrosis factor-α is a type II transmembrane protein that is released by active T…

The structures, antigen binding, and abilities to activate complement are important aspects to understand different drugs relating to autoimmune diseases. Each of the four drugs, infliximab, Adalimumab, Etanercept, and Certilizumab, have different antibody structures, leading to differences in function and binding abilities. The drug infliximab is a chimeric monoclonal antibody, containing 25% mouse-derived and 75% human-derived amino acids. The drug Adalimumab is a fully human monoclonal…

S feels some the side effects from medications are just as bad at the symptoms of Crohns. For example Humira (adalimumab) is a class of drug called disease-modifying antirheumatic drugs (DMARDs), an immunosuppressive drugs that interfere with natural immune function to reduce the inflammation in his colon (Burchum & Rosenthal, 2016). These types of medications increase the risk of infection and cancer (Burchum & Rosenthal, 2016). After taking Methotrexate (another DMARD), S developed lungs…

CASE STUDY3: INFLIXIMAB & ITS BIOSIMILAR Infliximab is a chimeric, anti-tumor necrosis factor monoclonal antibody which is effective in patients with active rheumatoid arthritis. Infliximab is traded under the name “remicade” and is originally licensed by Janssen. It works by binding to TNF-α and inhibits the binding of TNF-α with its receptor. TNF-α is a cytokine (chemical messenger) that is involved in systemic inflammation. CT-P13 (brand name- inflectra) is a biosimilar of infliximab…

DISCUSSION The aim of this study is to assess the efficacy of infliximab in the treatment of ulcerative colitis and to observe the presence of any side effects to infliximab. Infliximab tends to be used as a third-line therapy in patients with moderate to severe UC or as a rescue therapy [8]. However, experts have proposed that earlier use during less severe disease states (i.e., moderate UC) could benefit many patients [9] [10] [11]. Furthermore, infliximab can potentially attain the new…

Indeed, experts have noted that adjusting drug doses based on clinical symptoms is often inaccurate. Furthermore, multiple factors in addition to anti-drug antibodies may influence pharmacokinetics (e.g., gender, body size, disease severity, TNF burden, and serum albumin). Finally, maintenance of an optimal drug level is associated with improved clinical outcomes, suggesting a role for therapeutic drug monitoring in routine clinical practice. After dose optimization they demonstrated that…

to express to you the urgency in this matter. Debra is declining at a rapid pace and is in need of aggressive treatment. I believe she would benefit from Remicade in order to halt the rapid progression of her Rheumatoid Arthritis...” Final External Review Decision: The carrier’s decision in denying coverage for continued Remicade infusions 7 mg/kg every 6 weeks was not appropriate. The request to continue Remicade infusions 7 mg/kg every 6 weeks is medically necessary for the treatment…

Immunosuppressants like Azathioprine have been used successfully to induce and maintain remission. Azathioprine is a cytotoxic drug that interferes with both cell mediated and humoral immunity by suppressing the proliferation of B and T lymphocytes. Cytotoxic drugs are nonspecific, so they can destroy any proliferating cells. This can cause major adverse effects such as pancreatitis and neutropenia, so they are usually reserved for patients who have not responded well to other drug therapies…

Antibodies directed against TNF-α include infliximab (IFX), a monoclonal chimeric antibody, adalimumab (ADA) and golimumab (GLM), both humanized monoclonal antibodies. These therapy agents have been proven to be effective for obtaining and maintaining clinical remission in UC [10-12, 14, 15]. In ulcerative colitis, the benefit of the combination of anti-TNF-α agents with an IS (combination therapy) remains debated. In Crohn’s disease (CD), the SONIC trial, reported that there is superiority of…

susceptibility There are standard therapies: Employees should follow all workplace and safety guidelines and take any additional, appropriate steps to reduce their exposure to beryllium dust particles, fumes, and vapors. The treatment of the people with acute beryllkosis may include therapy with corticosteroid drugs, breathing support. The berylliosis for the chronic one is not yet done, there is no treatment for it. But physicians to ensure early detection of the chronic berylliosis and…